Genkyotex nets $21 mln Series D
Genkyotex, which develops selective NOX inhibitors, has closed $21 million in Series D funding. NeoMed Management, VI Partners and BioMedInvest led the round with participation from Edmond de Rothschild Investment Partners, Eclosion2 and Vesalius Biocapital Partners. In conjunction with the funding, Dr. Claudio Nessi of NeoMed has been added to Genkyotex’s board.
7 January 2015•2 mins read
